HighVista Strategies’s Cytokinetics CYTK Stock Holding History

HighVista Strategies’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.65M	Buy	78,003 +19,360	+33%	+$1.39M	1.52%	18
2026 Q1	$3.87M	Sell	58,643 -55,921	-49%	-$3.55M	1.07%	21
2025 Q4	$7.28M	Sell	114,564 -18,366	-14%	-$1.14M	1.87%	9
2025 Q3	$7.31M	Buy	132,930 +64,278	+94%	+$2.65M	1.79%	11
2025 Q2	$2.27M	Buy	68,652 +23,903	+53%	+$831K	0.83%	34
2025 Q1	$1.8M	Buy	44,749 +30,488	+214%	+$1.4M	0.69%	51
2024 Q4	$671K	Buy	14,261 +4,206	+42%	+$218K	0.25%	118
2024 Q3	$531K	Buy	+10,055	New	+$560K	0.18%	126
2022 Q4	–	Sell	-73,154	Closed	-$3.54M	–	109
2022 Q3	$3.54M	Buy	73,154 +5,652	+8%	+$272K	2.02%	12
2022 Q2	$2.65M	Buy	67,502 +1,733	+3%	+$69.8K	1.6%	19
2022 Q1	$2.42M	Buy	65,769 +30,537	+87%	+$1.09M	1.54%	18
2021 Q4	$1.61M	Buy	+35,232	New	+$1.36M	1.28%	19
2021 Q1	–	Sell	-47,520	Closed	-$987K	–	130
2020 Q4	$987K	Buy	+47,520	New	+$868K	0.63%	27

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's CYTK Position: Q2 2026 in Review

HighVista Strategies increased its Cytokinetics (CYTK) stake by 33% in Q2 2026, buying an estimated $1.39M and bringing the position to 78,003 shares worth $6.65M. The position accounts for 1.52% of the portfolio, ranked #18.

HighVista Strategies first reported a position in CYTK in Q4 2020 and has held it in 13 quarters since. The position peaked at $7.31M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

HighVista Strategies held 78,003 shares of Cytokinetics worth $6.65M as of Q2 2026.
HighVista Strategies bought 19,360 Cytokinetics shares in Q2 2026, an estimated $1.39M.
Cytokinetics made up 1.52% of HighVista Strategies's portfolio in Q2 2026, its #18 holding.
HighVista Strategies first reported a position in Cytokinetics in Q4 2020 and has held it in 13 quarters since.
HighVista Strategies's Cytokinetics position peaked at $7.31M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.